



Press Release April 10, 2019

Proposal to expand the Genovis Board of Directors at 2019 Annual General Meeting

The Nomination Committee proposes that Genovis should expand its Board of Directors at the 2019 Annual General Meeting. Under the proposal, two directors, Lotta Ljungqvist and Håkan Wickholm, will be elected.

Lotta Ljungqvist is CEO of GE Nordics and the Testa Center in Uppsala. She is the former CEO of IMED AB and global head of BioProcess R&D at GEHC Life Science. She has also held several project management positions at Pharmacia Corp & Pharmacia & Upjohn. Lotta sits on the Board of Directors for Vinnova, SwedenBIO, AmCham Sweden and Atlas Antibodies AB.

Håkan Wickholm has his own consultancy firm. He has 30 years of experience from senior positions in international pharmaceutical and biotechnology companies. Håkan has worked as Chief Business Officer (CBO) and CEO of Lytix Biopharma, as well as in various management positions for AstraZeneca, from which he gained strong international experience in strategy formulation, business development and commercialization.

“We are extremely pleased to be able to propose that the AGM bring on two such experienced and knowledgeable individuals to the Genovis Board of Directors. The company is in a dynamic phase and exciting new challenges lie ahead. We consider this proposal for two candidates with skills that complement and reinforce the Board to be extremely valuable,” says Mikael Lönn, chairman of the Nomination Committee.

The new Board of Directors in the proposal to the Annual General Meeting is as follows: Re-election of Mårten Winge, Kenth Petersson, Lena Söderström, Peter Hein and Mikael Lönn, and new election of Lotta Ljungqvist and Håkan Wickholm.

Lena Mårtensson Wernrud has declined re-election.

The Nomination Committee proposes re-election of Mårten Winge to serve as Chairman of the Board.

For more information, please contact:

Fredrik Olsson, CEO, Genovis AB

T: +46 (0)46-12 12 33

E: fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company's Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.